Three tablets contain: Evodia bitter root 59.74 mg •
Brand name products often contain multiple ingredients. To read detailed information about each ingredient, click on the link for the individual ingredient shown above.
In 2004, Canada began regulating natural medicines as a category of products separate from foods or drugs. These products are officially recognized as "Natural Health Products." These products include vitamins, minerals, herbal preparations, homeopathic products, probiotics, fatty acids, amino acids, and other naturally derived supplements.
In order to be marketed in Canada, natural health products must be licensed. In order to be licensed in Canada, manufacturers must submit applications to Health Canada including information about uses, formulation, dosing, safety, and efficacy.
Products can be licensed based on several criteria. Some products are licensed based on historical or traditional uses. For example, if an herbal product has a history of traditional use, then that product may be acceptable for licensure. In this case, no reliable scientific evidence is required for approval.
For products with non-traditional uses, some level of scientific evidence may be required to support claimed uses. However, a high level of evidence is not necessarily required. Acceptable sources of evidence include at least one well-designed, randomized, controlled trial; well-designed, non-randomized trials; cohort and case control studies; or expert opinion reports.
Finished products licensed by Health Canada must be manufactured according to Good Manufacturing Practices (GMPs) as outlined by Health Canada.
Below is general information about the effectiveness of the known ingredients contained in the product Ganmaoling Herbal Tablets For Flu. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
There is insufficient reliable information available about the effectiveness of evodia.
Below is general information about the safety of the known ingredients contained in the product Ganmaoling Herbal Tablets For Flu. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
There is insufficient reliable information available about the safety of evodia when used orally. In animal studies, evodia has induced QT interval prolongation and Torsade de pointes (97035). It is not clear what dose, if any, is required to produce a similar effect in humans.
PREGNANCY: POSSIBLY UNSAFE
when used orally.
Active constituents in evodia have uterine stimulant activity in animal models. Evodia might also decrease litter size in animal models (15229). Theoretically, taking evodia during pregnancy might adversely affect pregnancy outcome.
LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product Ganmaoling Herbal Tablets For Flu. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
Theoretically, taking evodia with antiplatelet or anticoagulant drugs might increase the risk of bruising and bleeding.
Details
|
Theoretically, evodia might decrease the levels and clinical effects of caffeine.
Details
In animal models, evodia extract decreases caffeine levels by up to 71%. Evodia extract induces hepatic cytochrome P450 1A2 (CYP1A2) enzyme, of which caffeine is a substrate (15241).
|
Theoretically, evodia might decrease the levels and clinical effects of chlorzoxazone.
Details
Animal research shows that administration of rutaecarpine, a constituent of evodia, with chlorzoxazone reduces the area under the curve (AUC) of chlorzoxazone by 84% and increases its clearance by 646%. This interaction is likely due to induction of cytochrome P450 2E1 (CYP2E1) by rutaecarpine (107913).
|
Theoretically, drugs that inhibit CYP1A2 might increase the levels and clinical effects of evodia.
Details
The evodia constituent rutaecarpine is metabolized by CYP1A2 (15253).
|
Evodia might reduce the levels and clinical effects of CYP1A2 substrates through induction of CYP1A2.
Details
|
Theoretically, evodia might reduce the levels and clinical effects of CYP2E1 substrates through induction of CYP2E1.
Details
Animal research suggests that rutaecarpine, a constituent of evodia, induces CYP2E1 activity. In rats, rutaecarpine increases markers of CYP2E1 activity, and administration of rutaecarpine with chlorzoxazone, a known CYP2E1 substrate, reduces the area under the curve (AUC) of chlorzoxazone by 84% and increases its clearance by 646% (107913).
|
Theoretically, taking CYP3A4 inducers might decrease the levels and clinical effects of evodia.
Details
Animal research shows that concomitant administration of dexamethasone, a known CYP3A4 inducer, with the alkaloid constituents of evodia significantly reduces the area under the curve (AUC), maximum concentration (Cmax), and half-life of these constituents (107911).
|
Theoretically, CYP3A4 inhibitors might increase the levels and clinical effects of evodia.
Details
Animal research shows that concomitant administration of ketoconazole, a known CYP3A4 inhibitor, with the alkaloid constituents of evodia significantly increases the area under the curve (AUC), maximum concentration (Cmax), and half-life of these constituents (107911).
|
Theoretically, evodia might increase the levels and clinical effects of CYP3A4 substrates.
Details
In vitro research shows that evodia extract inhibits hepatic CYP3A4 (15236). This effect has not been reported in humans.
|
Theoretically, evodia might have an additive effect with drugs that prolong the QT interval, potentially increasing the risk of ventricular arrhythmias.
Details
Evodia has demonstrated dose-dependent activity as a proarrhythmic agent in animal and in vitro studies. Evodia infusion in animals extends the action duration potential and induces prolongation of the QT interval and Torsade de pointes (97035).
|
Theoretically, evodia might decrease the levels and clinical effects of theophylline.
Details
The evodia constituent rutaecarpine decreases theophylline levels and half-life by about 70% in animal models (15227). This constituent appears to induce hepatic cytochrome P450 1A2 (CYP1A2) enzyme activity, of which theophylline is a substrate (15227,15230). Rutaecarpine is the primary active constituent of evodia; however, it is not known if the whole crude extract of evodia also causes this interaction.
|
Below is general information about the adverse effects of the known ingredients contained in the product Ganmaoling Herbal Tablets For Flu. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General ...There is no reliable evidence regarding the safety of evodia from clinical trials. In animal studies, evodia has induced QT prolongation and Torsade de pointes (97035).
Cardiovascular ...In animal studies, evodia acts as a proarrhythmic agent with a dose-dependent effect. Evodia infusion has resulted in QT prolongation and Torsade de pointes (97035). It is not clear what dose of evodia, if any, is required to produce a similar effect in humans.